Hospital Universitario Virgen de la Victoria
Málaga, Andalusia 29010
3 studies enrolling now · 13 studies all time
What they study most
Advanced Nonhaematologic Malignancies, Breast Cancer, Metastatic, Carcinoma, Renal Cell, Cardiovascular Diseases, Cervical Cancer, Chronic Kidney Disease, Gastric/Gastroesophageal Junction Adenocarcinoma, Lymphoma, Mantle-Cell, Melanoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer, Obesity
Studies at this site
- A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors — Recruiting now
- A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas — Recruiting now
- ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer — Recruiting now
- A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight — Completed
- A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease — Completed
- A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes — Completed
- Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) — Running, not enrolling
- A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities — Running, not enrolling
- Efficacy and Safety of Volenrelaxin in Adults With Chronic Kidney Disease — Withdrawn before enrolling
- A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin — Completed
- A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections — Completed
- Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors — Completed
- A Study of LY3209590 in Participants With Type 1 Diabetes — Completed